Evidence map›Paper›PMID 41282260›Full record

ArticleResearch square2025

A Preliminary Investigation of Brain Cannabinoid Receptor Type 1 (CB1R) Availability in Men with Opioid Use Disorder.

Anahita Bassir Nia, Ardavan Mohammad Aghaei, Jeremy Weleff, Julia Shi, Angelina Contreras, Mackenzie Griffin, Oluwole Jegede, Brian Pittman, Ilan Harpaz-Rotem, Ansel Hillmer and 1 more

Abstract readPreprint
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anahita Bassir NiaYale University School of Medicine.ORCID 0000-0002-3890-3518
Ardavan Mohammad Aghaei
Julia Shi
Angelina Contreras
Mackenzie Griffin
Brian PittmanYale School of Medicine.
Ilan Harpaz-RotemYale University.ORCID 0000-0002-6066-9406
Ansel HillmerUniversity of Michigan.ORCID 0000-0002-8105-1381
Deepak D'SouzaYale University.ORCID 0000-0003-3141-1462

Funding

SUBSTANCE ABUSEK12DA000167 · NIDA · YALE UNIVERSITY · PI STEPHANIE S O'MALLEY, Marc N Potenza · 1991 to 2026
$17.7M
Endocannabinoid System Alterations in Opioid Use Disorder (OUD)R21DA052864 · NIDA · YALE UNIVERSITY · PI BASSIR NIA, ANAHITA, D'SOUZA, DEEPAK CYRIL · 2022 to 2023
$461k
NIDA NIH HHS K12 DA000167NIDA NIH HHS R21 DA052864
6 · The paper itself

Abstract

The endocannabinoid (eCB) system has been proposed as a potential target for developing new medications for opioid use disorder (OUD). However, the status of the eCB system, specifically brain cannabinoid receptor type 1 (CB1R) in OUD, is unknown. In this study, CB1R availability was measured in males with OUD on stable opioid agonist treatment (OAT) (n = 10) versus healthy controls (HC) (n = 18), using High-Resolution Research Tomography (HRRT) and the CB1R-specific radiotracer, [

Indexed as

[11C]OMARCannabinoid Receptor type 1EndocannabinoidOpiatesOpioid Use DisorderPositron Emission Tomography

Identifiers

PMID41282260
PMCPMC12633167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.